From June 2017 to June 2019, researchers evaluated the safety and efficacy of CAR-T cell immunotherapy targeting Mesothelin, PSCA, CEA, HER2, MUC1, and EGFRvIII for pancreatic cancer. Here, ERBB2 is linked to familial pancreatic carcinoma.